Aptorum Group Limited (APM)
Stock Price:
$3.52 USD
-0.17 (-4.61%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
106.97M |
| Revenue (ttm) |
535,166 |
| Net Income (ttm) |
-18.69M |
| Shares Out |
7.95M |
| EPS (ttm) |
-0.64 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 11, 2020 |
| Last Price |
$3.52 |
| Previous Close |
$3.69 |
| Change ($) |
-0.17 |
| Change (%) |
-4.61% |
| Day's Open |
3.66 |
| Day's Range |
3.49 - 3.68 |
| Day's Volume |
86,249 |
| 52-Week Range |
1.66 - 18.26 |
More Stats
| Market Cap |
106.97M |
| Enterprise Value |
106.88M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
7.95M |
| Float |
4.73M |
| EPS (basic) |
-0.64 |
| EPS (diluted) |
-0.64 |
| FCF / Share |
-0.49 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
30,016 |
| Short Ratio |
0.19 |
| Short % of Float |
0.60% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
199.88 |
| PB Ratio |
6.59 |
| Revenue |
535,166 |
| Operating Income |
-18.20M |
| Net Income |
-18.69M |
| Free Cash Flow |
-14.22M |
| Net Cash |
86,797 |
| Net Cash / Share |
0.00 |
| Gross Margin |
-48.47% |
| Operating Margin |
-3,400.52% |
| Profit Margin |
-3,491.80% |
| FCF Margin |
-2,657.06% |
| ROA |
-32.95% |
| ROE |
-84.53% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$13.00*
(269.32% upside)
Low
11.0
Current: $3.52
High
15.0
Target: 13.00
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 0.54 | 0.38 |
| Revenue Growth | 39.57% | - |
| Gross Profit | -0.26 | 0.07 |
| Operating Income | -18.20 | -10.33 |
| Net Income | -18.69 | -14.83 |
| Shares Outstanding | 29.01 | 27.91 |
| Earnings Per Share | -0.64 | -0.53 |
| Operating Cash Flow | -13.38 | -10.04 |
| Capital Expenditures | -0.84 | -5.65 |
| Free Cash Flow | -14.22 | -15.68 |
| Cash & Equivalents | 6.56 | 27.24 |
| Total Debt | 6.47 | 10.30 |
| Net Cash / Debt | 0.09 | 16.94 |
| Assets | 23.95 | 45.07 |
| Liabilities | 9.10 | 12.33 |
| Book Value | 16.36 | 33.11 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aptorum Group Limited |
| Country |
Hong Kong |
| Employees |
36 |
| CEO |
Ian Huen |
Stock Information
| Ticker Symbol |
APM |
| Stock Exchange |
NASDAQ |
| Unique Identifier |
NASDAQ: APM |
| IPO Date |
December 18, 2018 |
Description
Aptorum Group Limited, a pharmaceutical company, develops and commercializes a range of therapeutic and diagnostic technologies to treat unmet medical needs. It focuses on developing various drug molecules and certain technologies for the treatment and diagnosis of human disease conditions in neurology, infectious diseases, gastroenterology, oncology, and other disease areas. The company also focuses on the development of surgical robotics and medical devices; and operating outpatient clinic. Aptorum Group Limited has a research and development agreement with Covar Pharmaceuticals to investigate 3 repurposed drug candidates (SACT-COV19) for coronavirus disease under existing Smart-ACT platform and Acticule infectious disease platform. Aptorum Group Limited was incorporated in 2010 and is headquartered in Hong Kong, Hong Kong.